Trial · NCT04761198
Participant flow35
How many started, completed or left each group, period by period.
1 to 20 of 35
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naive | 11 | |
| Overall Study | STARTED | Cohort B: Head and Neck Squamous Cell Carcinoma | 1 | |
| Overall Study | STARTED | Cohort C: Cervical Carcinoma | 8 | |
| Overall Study | STARTED | Cohort E: TMB-H + MSS Solid Tumors | 9 | |
| Overall Study | STARTED | Cohort F: Rare Tumors (Sarcoma, Uveal Melanoma, Germ Cell) | 33 | |
| Overall Study | STARTED | Cohort G: Endometrial Cancer Post- CPI (PD-1/PD-L1 Treated) | 4 | |
| Overall Study | STARTED | Cohort H: Ovarian Cancer | 10 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Cohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naive | 11 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Cohort B: Head and Neck Squamous Cell Carcinoma | 1 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Cohort C: Cervical Carcinoma | 8 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Cohort E: TMB-H + MSS Solid Tumors | 9 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Cohort F: Rare Tumors (Sarcoma, Uveal Melanoma, Germ Cell) | 33 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Cohort G: Endometrial Cancer Post- CPI (PD-1/PD-L1 Treated) | 4 | |
| Overall Study | Received at Least 1 Dose of Study Drug | Cohort H: Ovarian Cancer | 10 | |
| Overall Study | Response-Evaluable (RE) Analysis Set | Cohort A: Endometrial Cancer CPI (PD-1/PD-L1) Naive | 10 | |
| Overall Study | Response-Evaluable (RE) Analysis Set | Cohort B: Head and Neck Squamous Cell Carcinoma | 1 | |
| Overall Study | Response-Evaluable (RE) Analysis Set | Cohort C: Cervical Carcinoma | 8 | |
| Overall Study | Response-Evaluable (RE) Analysis Set | Cohort E: TMB-H + MSS Solid Tumors | 9 | |
| Overall Study | Response-Evaluable (RE) Analysis Set | Cohort F: Rare Tumors (Sarcoma, Uveal Melanoma, Germ Cell) | 31 | |
| Overall Study | Response-Evaluable (RE) Analysis Set | Cohort G: Endometrial Cancer Post- CPI (PD-1/PD-L1 Treated) | 3 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04761198/flow